SAN DIEGO & GRAND PRAIRIE, Texas--(BUSINESS WIRE)--Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Neos Therapeutics, Inc. (NASDAQGM: NEOS) violated federal securities laws in connection with its initial public offering ("IPO"). Neos, a pharmaceutical company, engages in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies.
Neos's Stock Price Falls
On July 23, 2015, Neos held its IPO, selling 4.8 million shares of stock and raising $72 million in new capital. However, since the IPO, Neos's stock has fallen from its high of $27.09 per share in August 2015 to close at $5.90 per share on October 31, 2016. The decline may be due to the fact that Neos's business operations and financial prospects were not as strong as represented in the company's Registration Statement that it filed with the U.S. Securities and Exchange Commission.
View this press release on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/neos-therapeutics-inc
Neos Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, DDonahue@robbinsarroyo.com, or via the shareholder information form on the firm's website.
Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.
Attorney Advertising. Past results do not guarantee a similar outcome.